Myeloproliferative neoplasm

Tefferi A. Challenges facing JAK inhibitor therapy for myeloproliferative neoplasms. N Engl J Med. 2012 366 844-6. 

Tang TC, Chang H, Chuang WY. Complete response of myeloid sarcoma with FIPlLl-PDGFRA-associated myeloproliferative neoplasms to imatinib mesylate monotherapy. Acta Haematol. 2012 128 83-7. 

Comprising a family of four cytoplasmic tyrosine kinase enzymes, JAKl, JAK2, JAKS, and tyrosine kinase 2 (TYK2), the Janus kinases QAKs) are important cell-signaling mediators in myeloid malignancies, inflammatoiy, and autoimmune diseases. Discovery of the V617F mutation in JAK2 in myeloproliferative neoplasm (MPN) patients catalysed rapid advances in JAK... 

Although tumor induction has mostly been documented in patients treated for cancer, long-term cyclophosphamide treatment for non-neoplastic conditions can also increase the incidence of certain neoplasms. Whether this oncogenic effect is a consequence of drug-induced chromosomal aberrations rather than immunosuppression is unclear. An increased incidence of bladder cancers, skin cancers, and myeloproliferative disorders was found in a 20-year follow-up study of 119 patients with rheumatoid arthritis, and a high dose of cyclophosphamide (mean total dose of 80 g) was the main susceptibihty factor (47). 

---